T1D Fund
The T1D Fund is a venture philanthropy fund dedicated to accelerating life-changing solutions to treat, prevent, and ultimately cure Type 1 Diabetes (T1D). Established in December 2016, the fund aims to attract and deploy capital to advance promising disease-modifying therapies and provide cures for those living with T1D. It is the first scaled, mission-driven venture philanthropy fund focused on equity investments in partnership with additional sources of capital, including venture capital, corporations, and foundations. The T1D Fund is strategically aligned with Breakthrough T1D, the leading global T1D research and advocacy organization, to support innovative approaches and novel mechanisms with curative potential.
What We Do
The T1D Fund invests in companies developing therapies to treat, prevent, and cure Type 1 Diabetes. The fund focuses on equity investments in partnership with venture capital, corporations, and foundations.
The fund uses a venture philanthropy model to create an investment market in T1D, accelerating life-changing solutions through strategic equity investments and disease expertise.
Fund Size
Industry Focus
Portfolio
Aspect Biosystems is pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine. The company closed a US$115 million Series B financing round to advance multiple bioprinted tissue therapeutics towards the clinic.
#Biotechnology
DiogenX focuses on regenerating insulin-producing beta cells for the treatment of diabetes. The company raised €27.5 million in Series A financing to advance its lead drug candidate towards clinical development in patients with type 1 diabetes.
#Biotechnology
Egle Therapeutics is advancing the next generation of regulatory T cell-focused therapies for oncology and autoimmune diseases. The company appointed Christophe Quéva, Ph.D., as Chief Executive Officer to lead its transition into clinical-stage development.
#Biotechnology
GluSense is developing a long-lasting injectable glucose sensor for the treatment of type 1 diabetes. The T1D Fund's investment will be used to bring the Glyde CGM closer to the first in-human clinical trial.
#Medical Devices
Inversago Pharma is a clinical-stage biotech company with a unique portfolio of CB1 inverse agonists, focusing on metabolic conditions such as Diabetic Nephropathy and Type 1 Diabetes. The company is involved in a Phase 1b clinical trial for its lead molecule, INV-202.
#Biotechnology
Mozart Therapeutics is developing CD8 Treg modulators for autoimmune diseases. The company completed a Phase 1a study of MTX-101, showing it is well tolerated and selectively activates CD8 Treg.
#Biotechnology